Trials / Completed
CompletedNCT00189774
Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the superiority of nateglinide over placebo for inadequately controlled type 2 diabetic patients with pioglitazone treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | nateglinide |
Timeline
- First posted
- 2005-09-19
- Last updated
- 2008-03-13
Locations
7 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00189774. Inclusion in this directory is not an endorsement.